Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 3/20 | 0.48 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.47 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.47 |
| ▸ | GGPS1 | O95749 | 4/20 | 0.44 |
| ▸ | FDPS | P14324 | 2/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.38 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.38 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL409303 | 1.00 | DNM1 (0.48) | DNM1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL5494441 | 0.79 | MAPT (0.32) | TSHR | |
| SCHEMBL1566639 | 0.77 | DNM1 (0.48) | DNM1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL10946036 | 0.72 | DNM1 (0.43) | DNM1S1PR2S1PR1S1PR3S1PR5 | |
| Hexane SCHEMBL28668676 | 0.71 | TSHR (0.50) | FDPSLPAR3LPAR2SMPD1TSHR | |
| SCHEMBL9346534 | 0.70 | — | — | |
| SCHEMBL3842323 | 0.70 | MMP1 (0.43) | DNM1S1PR2S1PR1S1PR3S1PR5 | |
| Dymanthine SCHEMBL8374472 | 0.70 | DNM1 (0.71) | DNM1S1PR2S1PR1S1PR3S1PR5 | |
| Phosphoric Acid SCHEMBL7074541 | 0.70 | DNM1 (0.71) | DNM1S1PR2S1PR1S1PR3S1PR5 | |
| Phosphoric Acid SCHEMBL19812153 | 0.70 | S1PR2 (0.77) | DNM1S1PR2S1PR1S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11732259-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11732259-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20220127613-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | SAREPTA THERAPEUTICS INC (US) | 2022-04-28 | — | — | US | disclosed |
| US-11225662-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-11208655-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20210139896-A1 | Peptide Oligonucleotide Conjugates | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2021-05-13 | — | — | US | disclosed |
| US-20200277598-A1 | Peptide Oligonucleotide Conjugates | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-09-03 | — | — | US | disclosed |
| US-10760078-B2 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | SAREPTA THERAPEUTICS, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20200115709-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-04-16 | — | — | US | disclosed |
| US-20190218551-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2019-07-18 | — | — | US | disclosed |
| US-20140330006-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | SAREPTA THERAPEUTICS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-8779128-B2 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | SAREPTA THERAPEUTICS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8779128-B2 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | SAREPTA THERAPEUTICS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| WO-2013074834-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | SAREPTA THERAPEUTICS, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
| US-20120289457-A1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | AVI BIOPHARMA, INC. (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120289457-A1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | AVI BIOPHARMA, INC. (US) | 2012-11-15 | — | — | US | disclosed |
| WO-2012150960-A1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | AVI BIOPHARMA, INC. (US) | 2012-11-08 | — | — | WO | disclosed |
| US-20120065169-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2012-03-15 | — | — | US | disclosed |
| US-20120065169-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2012-03-15 | — | — | US | disclosed |
| WO-2011150408-A2 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | AVI BIOPHARMA, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218551-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | NSUN2, UPF1, RTCB | DNM1 2546/4885S1PR2 4191/4885S1PR1 4020/4885 |
| US-20120065169-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | NSUN2, UPF1, RTCB | DNM1 2546/4885S1PR2 4191/4885S1PR1 4020/4885 |
| US-20200277598-A1 | Peptide Oligonucleotide Conjugates | SNRPE, SMN1; SMN2, UPF1 | DNM1 1981/4885S1PR2 3650/4885S1PR1 3444/4885 |
| US-11208655-B2 | Functionally-modified oligonucleotides and subunits thereof | RTCB, NSUN3, NSUN2 | DNM1 3480/4885S1PR2 4033/4885S1PR1 3843/4885 |
| US-20140330006-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | RTCB, NSUN3, NSUN2 | DNM1 3480/4885S1PR2 4033/4885S1PR1 3843/4885 |
| US-10760078-B2 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | NSUN2, UPF1, RTCB | DNM1 2546/4885S1PR2 4191/4885S1PR1 4020/4885 |
| US-20210139896-A1 | Peptide Oligonucleotide Conjugates | SNRPE, SMN1; SMN2, UPF1 | DNM1 1981/4885S1PR2 3650/4885S1PR1 3444/4885 |
| US-20200115709-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | RTCB, NSUN3, NSUN2 | DNM1 3480/4885S1PR2 4033/4885S1PR1 3843/4885 |
| US-20120289457-A1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | SNRPE, SMN1; SMN2, UPF1 | DNM1 1981/4885S1PR2 3650/4885S1PR1 3444/4885 |
| US-20220127613-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | RTCB, NSUN3, NSUN2 | DNM1 3480/4885S1PR2 4033/4885S1PR1 3843/4885 |
| US-11225662-B2 | Peptide oligonucleotide conjugates | SNRPE, SMN1; SMN2, UPF1 | DNM1 1981/4885S1PR2 3650/4885S1PR1 3444/4885 |
| US-11732259-B2 | Peptide oligonucleotide conjugates | SNRPE, SMN1; SMN2, UPF1 | DNM1 1981/4885S1PR2 3650/4885S1PR1 3444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.